

A Review on the Reconstruction of Articular Cartilage Using Collagen Scaffolds

Received for publication, May 05, 2015

Accepted, July 22, 2015

**HOREA BENE¹, GHEORGHE TOMOAI¹,
OLGA SORITAU², ROXANA-DIANA PASCA^{1,3}**

¹Iuliu Hatieganu University of Medicine and Pharmacy, Orthopedic Department, Cluj-Napoca, Romania; ²“Prof. Dr. Ion Chiricuță” Oncology Institute, Cluj-Napoca, Romania; ³Chemical Engineering Department, Babes-Bolyai University of Cluj-Napoca; **Address correspondence to:** 11 Arany Janos St., 400028, Cluj-Napoca, Romania; roxana_diana_pasca@yahoo.com

Abstract

The reconstruction of articular cartilage has a great importance since more and more people are affected by osteoarticular diseases. Among these, osteoarthritis occupies a central place and affects mostly mature patients. Cartilage contains a significant quantity of collagen, so a first step in osteochondral reconstruction is represented by the developing of new materials based on collagen that can be used as implants in hard tissue engineering. There are many possibilities to construct biomaterials containing collagen, depending on the purpose. The collagen scaffolds prepared must have a series of characteristics such as biocompatibility and osseointegration. Before use, those scaffolds have to be well chemically characterized and tested in vitro experiments on cell cultures (chondrocytes are responsible for the cartilage regeneration) and in vivo studies on animal models (especially rats). The most important ways to prepare collagen scaffolds that can be used in the articular cartilage reconstruction are reviewed here.

Keywords: cartilage, collagen, scaffolds, osteoarthritis, reconstruction, cells, chondrocytes

1. Introduction

More than 10% of the population having over 60 years is affected by osteoarthritis in USA and the number is increasing due to the obesity risk and the modern life style (K.E. Keenan & al [1]).

There are three different types of cartilage: hyaline, fibrocartilaginous and elastic. Cartilage contains interstitial fluids (75%) and has a macromolecular network containing collagen (20% of the cartilage volume) and proteoglycans (glycosaminoglycans). Chondrocytes are the cells accountable for the synthesis and maintaining the cartilage, and represent about 1% of its volume (E.B. Hunziker & al [2]). The progress of osteoarthritis is associated with the changes in structure and orientation of collagen and with the loss of proteoglycans (A. Hanifi & al [3]).

The cartilage matrix can be determined using specific methods such as: T2 mapping, delayed gadolinium-enhanced MR imaging of cartilage (dGEMRIC), sodium imaging, T1ρ imaging, diffusion-weighted imaging, (M.D. Crema & al [4]), radiography, CT arthrography, ultrasonography (V. Jurans & al [5]). The collagen content extracted from cartilage can be evaluated using different techniques: high performance liquid chromatography (HPLC), mass spectroscopy (MS), and Fourier transform infrared spectroscopy (FTIR) (A. Hanifi & al [3]).

The reparation of the cartilage affected by osteoarthritis can be accomplished using biological products such as: mesenchymal stem cells namely mature adipocytes (J. Bushmann & al [6], A.M. Rogriguez & al [7], M.E. Fernyhough & al [8], L. Danisovic & al [9], Z. Alharbi & al [10], D. Zheng & al [11], M. Maumus & al [12]) or platelet-rich plasma, an autologous blood plasma injected in cartilage having the capacity to regenerate the cartilage (N.A. Smyth &

al [13], B.A. Tinsley & al [14], K. Akeda & al [15], Y. Mifune & al [16], B.J. Cole & al [17], J. De La Mata & al [18]).

2. Collagen scaffolds for cartilage reconstruction

One of the causes for the weak tendency of the defects in articular cartilage to heal spontaneously is the absence of a sufficient number of chondrocytes to get into the lesion and the lack of a temporary fibrin scaffold to accommodate the relocation of cells into the defect. This situation can lead to osteoarthritis and to the necessity of a total joint replacement.

The cartilage repair (S. N. Redman & al [19], A. Matsiko & al [20]) can be enhanced by using the methods of tissue engineering, namely the use of cell seeded scaffolds (S. Frenkel & al [21]). Scaffolds in cartilage tissue engineering are used in the shape of either hydrogels (C. G. Williams & al [22], D. Bosnakovski & al [23]) or porous matrices (W.J. Li & al [24], E. Steck & al [25], Y. Wang & al [26], M. Liu & al [27]). The 3D scaffolds implanted in cartilage are made of porous materials, and besides being a delivery vehicle for cells, growth factors or genes, they reinforce structurally the defect and prevent neighboring tissue to access it (S.M. Vickers & al [28]).

The scaffold's construction defines the ultimate shape of the newly grown tissue. Since the thickness of human articular cartilage is in the range from less than 500 μm up to 7.1 mm (B. Kladny & al [29]), the thickness of the scaffold for cartilage should fit the thickness of defects, to allow easy cell seeding and have good mechanical properties as an initial cell support (G. Chen & al [30]).

The biomechanical properties of articular cartilage imply the capability to restore its shape and recover into its structure the lost liquids, after loading. This is therefore a crucial quality for a scaffold (B. Kinner & al [31], C. Vinatier & al [32]). For the construction of the scaffolds (Z. Cao & al [33]) both natural materials: collagen, gelatin, fibrin, chitosan, alginate, hyaluronan, agarose, silk (H.A. Awad & al [34], Y. Wang & al [26], D. Bosnakovski & al [23], G.R. Ragetly & al [35]) and synthetic biodegradable macromolecules (polylactic acid, polyglycolic acid, polycaprolactone (G. Chen & al [36]) were used.

But fibrin is difficult to attach to the graft (D.H. Hendrickson & al [37]), and hyaluronan with chondrocytes (D. Robinson & al [38]) also has no adhesive qualities and little stiffness to assure their fastening on large defects. Collagen seems to be the most promising biomaterial for scaffolds, since it presents a natural adhesion to the cells surface, and contains biological information able to direct the activity of cells. Collagen is the main component of the articular cartilage extracellular matrix, which plays an important role in maintaining the chondrocyte phenotype and supporting the chondrogenesis, both in vitro and in vivo. (T. Minas & al [39], S. Nehrer & al [40], S. Wakitani & al [41], C.J. Hunter & al [42]). Moreover, collagen is known for its excellent biocompatibility and low antigenicity (C.H. Lee & al [43]) and its degradation products are not dangerous for the organism.

In the preparation of scaffolds, collagen fibrils have to be cross-linked, in order to improve its mechanical properties and to slow its degradation (L. Ma & al [44]). Physical methods, such as ultraviolet irradiation (K.S. Weadock & al [45]) or gamma rays irradiation (B.C. Liu & al [46]) are less effective. So cross linking is achieved mostly by using different compounds as chemical agents such as glutaraldehyde (L. Ma & al [47]), diisocyanate, diepoxide, formaldehyde, N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride (S. N. Park & al [48]).

For instance, this last agent was used for the chemical cross-linking of refibrillized jellyfish collagen to give porous scaffolds (B. Hoyer & al [49]). There is an increasing

tendency to use as cross-linker genipin – a natural product much less toxic than glutaraldehyde and epoxides (F.L. Mi & al [50], Y. Yuan & al [51], V. Chiono & al [52], L.P. Yan & al [53], L. Bi & al [54]).

Chondrocyte allografts were used in combination with collagen (S. Wakitani & al [55]) to resurface articular cartilage defects. A fibrin matrix with chondrocytes was also applied and produced repair tissues with 62% type II collagen content (D.H. Hendrickson & al [37]).

There are many examples for the use of different collagen scaffolds with chondrocytes (S. Mizuno & al [56], M. Ochi & al [57], C.R. Lee & al [58], P. Cherubino & al [59], S. Andereya & al [60]). On bovine type I collagen scaffolds, murine chondroprogenitor cells were cultured *in vitro*, and after being embedded with chondrocytes were implanted in articular defects in rabbits (S. Maor & al [61], A. Ben-Yishay & al [62]). A similar procedure was applied with equine chondrocytes embedded in collagen scaffolds and cultured *in vitro* (A.J. Nixon & al [63]). Collagen scaffolds give the necessary stiffness for the implant to be pressed securely into the defect. Scaffolds made of chondrocyte-collagen composites, obtained by culturing chondrocytes in expanded collagen scaffolds, were tested in articular defects (A.E. Sams & al [64], A.E. Sams & al [65]). They improved the cartilage healing in extensive defects, but their long-term durability is doubtful.

A type II collagen-glycosaminoglycan scaffold was used as a nonviral gene delivery vehicle for the gene transfer to seeded adult articular chondrocytes, to produce an elevated, prolonged and local expression of insulin-like growth factor (IGF)-1 for enhancing cartilage regeneration. (R.M. Capito & al [66]). Chondrocyte-seeded type II collagen scaffolds were used *in vitro*, and the effects of scaffold cross-link density and bioreactor culture environment on chondrogenesis were evaluated (S.M. Vickers [28]), as well as their mechanical properties (C.R. Lee & al [58]).

Mixtures of collagen with the amine groups containing polysaccharide chitosan, also a natural and biodegradable polymer, were also often used (S.S. Silva & al [67]). Scaffolds made from collagen and chitosan, and cross-linked with genipin were also investigated to find the effects of the preparative method on properties such as porosity, swelling rate, degradation rate, mechanical properties and biocompatibility (L.P. Yan & al [53], L. Bi & al [54]). Hyaluronan was also added to collagen scaffolds, and the obtained 3D sponges were injected with chondrocytes and investigated *in vitro* in order to identify mechanisms by which extracellular matrix molecules influence chondrocyte function (F. Allemann & al [68]).

The effect of pore size in collagen porous scaffolds was investigated (Q. Zhang & al [69]) and no obvious effect on cell proliferation and adhesion was found, but there were different effects on cartilage tissue regeneration. Three cartilage repair techniques were compared experimentally: treatment with a cell-free collagen type-I gel, a collagen type-I gel seeded with autologous chondrocytes, and abrasion arthroplasty (U. Schneider & al [70]). The implantation of the cell-free collagen gel lead to a high-quality repair tissue that equals a cell-based procedure after 1 year postoperatively. The study demonstrates the high chondrogenic potential of the collagen gel.

Also collagen type I gels or scaffolds without cells, but combined with marrow stimulation techniques have been used successfully for cartilage repair (L. de Girolamo & al [71], J.P. Benthien & al [72], J.P. Benthien & al [73], J. Gille & al [74], A.A. Dhollander & al [75], T. Efe & al [76], T. Kusano & al [77]). Atelocollagen - a highly purified type I collagen from which pepsin and telopeptid were removed to make it nonimmunogenic - mixed with fibrinogen and thrombin, was used in autologous collagen-induced chondrogenesis technique for cartilage repair (A.A. Shetty & al [78]). Along with collagen, chitosan was often used,

single or mixed with other biomacromolecules, such as alginates (P.B. Malafaya & al [79], N. Iwasaki & al [80]). A collagen-glycosaminoglycan (GAG) scaffold was used as an analog of extracellular matrix *in vitro* (J.M. Zaleskas & al [81]).

On the other hand, tissue engineering used also scaffolds made from synthetic - but biocompatible and biodegradable polymers, such as the polyesters: poly(lactic acid) – PLA, poly(glycolic acid) - PGA, or their copolymer poly(dl-lactic-co-glycolic acid) –PLGA, these can be easily formed into designed shapes in which chondrocytes or differentiated stem cells were seeded. Such constructs are then implanted in the defect articulation (D.W. Hutmacher & al [82]).

Other synthetic polymers were also used to this aim, single or in combination with natural compounds (F.T. Moutos & al [83]), for instance as polyurethane (Z. Li & al [84]), poly (ϵ -caprolactone) – PCL with starch (J.T. Oliveira & al [85]), or PCL and collagen (P. Prabu & al [86]). While synthetic polymers have relatively hydrophobic surfaces, a disadvantage for cell seeding, scaffolds from natural polymers such as collagen have hydrophilic surfaces, beneficial to cell seeding and cell attachment.

But these natural macromolecules present lower mechanical properties in the implants. Therefore combinations of the two kinds of materials, a hybrid scaffold comprising a highly hydrophilic natural component together with a fibrous synthetic component with higher strength should give better results. Such hybrids can contain a two-dimensional synthetic fiber component (G. Chen & al [30], W. Dai & al [87]), or a three-dimensional structure formed from the synthetic component, using a non-fibrous method, for example salt leaching (T. Sato & al [88], G. Chen & al [89]).

A composite made from collagen with PLGA fibers was used for tissue engineering of articular cartilage with the thickness adjustable between 200 μ m and 8 mm (G. Chen & al [90], G. Chen & al [30]). The PLGA forms a strong knitted mesh, with the role of a skeleton, including in its openings the web-like collagen microsponges, which facilitate cell seeding, cell distribution, and tissue formation. A blend of poly (L-lactide)-g-chondroitin sulfate with poly (L-lactide) was applied in cartilage tissue engineering (C.T. Lee & al [91]).

Another composite biomaterial made from synthetic and natural polymers was poly (ϵ -caprolactone)-graft-type II collagen-graft-chondroitin sulfate (PCL-g-COL-g-CS) (K. Y. Chang & al [92]) was used as a biomimetic matrix, which promoted the spreading and growth of chondrocytes. Scaffolds for cartilage tissue engineering were prepared from hybrid materials made of polyester, collagen and chitosan: collagen/PLA, chitosan/PLA, and collagen/chitosan/PLA (A.M. Haaparanta & al [93]).

The use of autologous chondrocytes cells on scaffolds for the repair of cartilage defects is limited by the induction of morbidity at the donor site and the instability in monolayer cultivation (M. Keeney & al [94]). An alternative to these is the use of mesenchymal stem cells from various tissues, such as bone marrow (T. Mimura & al [95]) or adipose tissue [Keeney 2011]. This problem is now intensely investigated in cartilage tissue engineering (C.G. Williams & al [22], W.J. Li & al [24], S.M. Vickers & al [28]). A concentration-gradient collagen scaffold was devised showed enhanced efficiency in the transport of mesenchymal stem cells to the central region of the full-thickness cartilage defects improving its regeneration (T. Mimura & al [95]).

Collagen and mixed scaffolds were also used for the transfer of other therapeutic materials, for the transport of DNA, collagen scaffolds were used for instance (R.E. Samuel & al [96]), but also scaffolds made from synthetic polymers, such as PLGA (L.D. Shea & al [97], J. H. Jang & al [98], Y. K. Luu & al [99]), poly(D,L-lactide)–poly (ethyleneglycol)

(PLA–PEG) [Y.K. Luu & al [99]). A porous collagen scaffold hybridized with PLGA microbeads loaded with insulin was prepared to be used for the release of insulin for application to cartilage tissue regeneration. (H.S. Nanda & al [100]).

3. Conclusions

Nowadays, the use of scaffolds is the principal technique in articular cartilage repair. Both natural (mostly collagen) and synthetic materials are used in the construction of scaffolds, but hybrid materials give the best results. Cross linking and the selection of the suitable agent is important in the manufacture of scaffolds. The scaffolds reinforce structurally the defect and serve as vehicle for the transport of chondrocytes, mesenchymal stem cells or other bioactive agents.

4. Acknowledgments:

MD Horea Benea, acknowledges the “Iuliu Hatieganu” University of Medicine and Pharmacy, 8th Department of Surgical Specialties: Orthopedics and Traumatology, Cluj-Napoca, Romania, for the internal grant no. 4994/4/08.03.2016

References

1. K. E. KEENAN, T. F. BESIER, J. M. PAULY, E. HAN, J. ROSENBERG, R. L. SMITH, S. L. DELP, G. S. BEAUPRE, G. E. GOLD, Prediction of Glycosaminoglycan Content in Human Cartilage by Age, T1 ρ and T2 MRI, *Osteoarthritis Cart.*, 19, 171, 179 (2011).
2. E. B. HUNZIKER, T. M. QUINN, H. J. HAUSELMANN, Quantitative structural organization of normal adult human articular cartilage. *Osteoarthritis Cart.*, 10, 564, 572 (2002).
3. A HANIFI, H. MCCARTHY, S. ROBERTS, N. PLESHKO, Fourier Transform Infrared Imaging and Infrared Fiber Optic Probe Spectroscopy Identify Collagen Type in Connective Tissues. *Plos One*, 8(5) 64822 (2013).
4. M. D. CREMA, F. W. ROEMER, M. D. MARRA, D. BURSTEIN, G. E. GOLD, F. ECKSTEIN, T. BAUM, T. J. MOSHER, J. A. CARRINO, A. GUERMAZI, Articular Cartilage in the Knee: Current MR Imaging Techniques and Applications in Clinical Practice and Research. *Radiography*, 31, 37, 61 (2011).
5. V. JURAS, M. BITTSANSKY, Z. MAJDISOVA, P. SZOMOLANYI, I. SULZBACHER, S. GÄBLER, J. STAMPFL, G. SCHÜLLER, S. TRATTNIG, In vitro determination of biomechanical properties of human articular cartilage in osteoarthritis using multi-parametric MRI, *J. Magn. Reson.* 197, 40, 47 (2009).
6. I. J. BUSCHMANN, S. GAO, L. HÄRTER, S. HEMMI, M. WELTI, C. M. L. WERNER, M. CALCAGNI, P. CINELLI, G. A. WANNER, Yield and proliferation rate of adipose-derived stromal cells as a function of age, body mass index and harvest site—increasing the yield by use of adherent and supernatant fractions?. *Cytotherapy*, 15, 1098, 1105 (2013).
7. A. M. RODRIGUEZ, C. ELABD, E. Z. AMRI, G. AILHAUD, C. DANI, The human adipose tissue is a source of multipotent stem cells. *Biochimie*, 87, 125, 128 (2005).
8. M. E. FERNYHOUGH, G. J. HAUSMAN, L. L. GUAN, E. OKINE, S. S. MOORE, M. V. DODSON, Mature adipocytes may be a source of stem cells for tissue engineering. *Biochem. Biophys. Res. Comm.*, 368, 455, 457 (2008).
9. L. DANISOVIC, I. VARGA, S. POLAK, Growth factors and chondrogenic differentiation of mesenchymal stem cells. *Tissue and Cell.*, 44, 69, 73 (2012).
10. Z. ALHARBI, C. OPLANDER, S. ALMAKADI, A. FRITZ, M. VOGT, N. PALLUA, Conventional vs. micro-fat harvesting: How fat harvesting technique affects tissue-engineering approaches using adipose tissue-derived stem/stromal cells. *J. Plast. Reconstruct. Aesthet. Surg.*, 66, 1271, 1278 (2013).
11. D. ZHENG, Y. DAN, S. YANG, G. LIU, Z. SHAO, C. YANG, B. XIAO, X. LIU, S. WU, T. ZHANG, P. K. CHU, Controlled chondrogenesis from adipose-derived stem cells 4 by recombinant transforming growth factor- β 3 fusion protein 5 in peptide scaffolds. *Acta Biomater.*, 11, 191, 203 (2015).
12. M. MAUMUS, C. MANFERDINI, K. TOUPET, J. A. PEYRAFITTE, R. FERREIRA, A. FACCHINI, E. GABUSI, P. BOURIN, C. JORGENSEN, G. LISIGNOLI, D. NOËL, Adipose mesenchymal stem cells protect chondrocytes from degeneration associated with osteoarthritis. *Stem Cell Res.*, 11, 834, 844 (2013).
13. N. A. SMYTH, C. D. MURAWSKI, L. A. FORTIER, B. J. COLE, J. G. KENNEDY, Platelet-Rich Plasma in the Pathologic Processes of Cartilage: Review of Basic Science Evidence, *J. Arthroscop. Rel. Surg.*, 29(8), 1399, 1409 (2013).

14. B. A. TINSLEY, J. V. FERREIRA, A. G. DUKAS, A. D. MAZZOCCA, Platelet-Rich Plasma Nonoperative Injection Therapy—A Review of Indications and Evidence. *Oper. Tech. Sports Med.*, 20(2), 192, 200, (2012).
15. K. AKEDA, H. S. AN, M. OKUMA, M. ATTAWIA, K. MIYAMOTO, E. J-M. A. THONAR, M. E. LENZ, R. L. SAH, K. MASUDA, Platelet-rich plasma stimulates porcine articular chondrocyte proliferation and matrix biosynthesis. *Osteoarthritis Cart.*, 14, 1272, 1280 (2006).
16. Y. MIFUNE, T. MATSUMOTO, K. TAKAYAMA, S. OTA, H. LI, L. B. MESZAROS, A. USAS, K. NAGAMUNE, B. GHARAIBEH, F. H. FU, J. HUARD, The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair *Osteoarthritis Cart.*, 21, 175, 185 (2013).
17. B. J. COLE, S. T. SEROYER, G. FILARDO, S. BAJAJ, L. A. FORTIER, Platelet-Rich Plasma: Where Are We Now and Where Are We Going?. *Sports Health*, 2(3) 203, 210 (2010).
18. J. DE LA MATA, Platelet Rich Plasma. A New Treatment Tool for the Rheumatologist?. *Reumatol. Clin.*, 9(3), 166, 171 (2013).
19. S. N. REDMAN, S. F. OLDFIELD, C. W. ARCHER, Current Strategies for Articular Cartilage Repair. *Eur. Cells Mater.*, 9, 23, 32 (2005).
20. A. MATSIKO, T.J. LEVINGSTONE, F.J. O'BRIEN, Advanced Strategies for Articular Cartilage Defect Repair. *Materials*, 6, 637, 668 (2013).
21. S. FRENKEL, P.E. DI CESARE, Scaffolds for articular cartilage repair. *Annals Biomed. Eng.*, 32(1) 26, 34 (2004).
22. C. G. WILLIAMS, T. K. KIM, A. TABOAS, A. MALIK, P. MANSON, J. ELISSEEFF, In vitro chondrogenesis of bone marrow-derived mesenchymal stem cells in a photopolymerizing hydrogel. *Tissue Eng.*, 9(4), 679, 688 (2003).
23. D. BOSNAKOVSKI, M. MIZUNO, G. KIM, S. TAKAGI, M. OKUMURA, T. FUJINAGA. Chondrogenic differentiation of bovine bone marrow mesenchymal stem cells (MSCs) in different hydrogels: influence of collagen type II extracellular matrix on MSC chondrogenesis, *Biotechnol. Bioeng.*, 93(6), 1152, 1163 (2006).
24. W. J. LI, R. TULI, C. OKAFOR, A. DERFOUL, K. G. DANIELSON, D. J. HALL, R. S. TUANA, A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells. *Biomaterials*, 26(6), 599, 609 (2005).
25. E. STECK, H. BERTRAM, A. WALTHER, K. BROHM, B. MROZIK, M. RATHMANN, C. MERLE, M. GELINSKY, W. RICHTER, Enhanced biochemical and biomechanical properties of scaffolds generated by flock technology for cartilage tissue engineering. *Tissue Eng. A*, 16(12), 3697, 3707 (2010).
26. Y. WANG, U. J. KIM, D. J. BLASIOLI, H. J. KIM, D. L. KAPLAN, In vitro cartilage tissue engineering with 3D porous aqueous-derived silk scaffolds and mesenchymal stem cells. *Biomaterials*, 26(34), 7082, 7094 (2005).
27. M. LIU, X. YU, F. HUANG, S. CEN, G. ZHONG, Z. XIANG, Tissue Engineering Stratified Scaffolds for Articular Cartilage and Subchondral Bone Defects Repair. *Orthopedics*, 36 (11), 868, 873 (2013).
28. S.M. VICKERS, Cell-seeded type II collagen scaffolds for articular cartilage tissue engineering, PhD Thesis, Massachusetts Institute of Technology, (2007). <http://hdl.handle.net/1721.1/38926>
29. B. KLADNY, P. MARTUS, K. H. SCHIWY-BOCHAT, G. WESELOH, B. SWOBODA, Measurement of cartilage thickness in the human knee-joint by magnetic resonance imaging using a three-dimensional gradient-echo sequence. *Int. Orthop.*, 23, 264, 267 (1999).
30. G. CHEN, T. SATO, T. USHIDA, R. HIROCHIKA, Y. SHIRASAKI, N. OCHIAI, T. TATEISHI, The use of a novel PLGA fiber/collagen composite web as a scaffold for engineering of articular cartilage tissue with adjustable thickness. *Biomed. Mater. Res.*, 67, 1170, 1180, (2003).
31. B. KINNER, R. M. CAPITA, M. SPECTOR, Regeneration of articular cartilage. *Adv. Biochem. Eng. Biotechnol.*, 4, 91–123 (2005).
32. C. VINATIER, D. MRUGALA, C. JORGENSEN, J. GUICHEUX, L. D. NOE, Cartilage engineering: a crucial combination of cells, biomaterials and biofactors. *Trends Biotechnol.* 27, 307, 314 (2009).
33. Z. CAO, C. DOU, S. DONG, Scaffolding Biomaterials for Cartilage Regeneration. *J. Nanomater.*, Article ID 489128, (2014).
34. H. A. AWAD, M. Q. WICKHAM, H. A. LEDDY, J. M. GIMBLE, F. GUILAK, Chondrogenic differentiation of adipose-derived adult stem cells in agarose, alginate, and gelatin scaffolds. *Biomaterials*, 25(16), 3211, 3222 (2004).
35. G. R. RAGETLY, D. J. GRIFFON, H. B. LEE, L. P. FREDERICKS, W. GORDON-EVANS, Y. S. CHUNG, Effect of chitosan scaffold microstructure on mesenchymal stem cell chondrogenesis. *Acta Biomater.*, 6(4), 1430–1436 (2010).
36. G. CHEN, T. USHIDA, T. TATEISHI, Scaffold design for tissue engineering. *Macromol. Biosci.*, 2, 67, 77 (2002).
37. D. H. HENDRICKSON, A. J. NIXON, D. A. GRANDE, R. J. TODHUNTER, R. M. MINOR, H. ERB, G. LUST, Chondrocyte-Fibrin matrix transplants for resurfacing extensive articular cartilage defects. *J. Orthop. Res.*, 12, 485, 497 (1994).

38. D. ROBINSON, N. HALPERIN, Z. NEVO, Regenerating hyaline cartilage in articular defects of old chickens using implants of embryonal chick chondrocytes embedded in a new natural delivery substance. *Calcif. Tiss. Int.*, 46, 246,253 (1990).
39. T. MINAS, S. NEHRER, Current concepts in the treatment of articular cartilage defects. *Orthopedics*, 20, 525, 538 (1997).
40. S. NEHRER, H. A. BREINAN, A. RAMAPPA, S. SHORTKROFF, G. YOUNG, T. MINAS, C. B. SLEDGE, I. V. YANNAS, M. SPECTOR, Canine chondrocytes seeded in type I and type II collagen implants investigated in vitro. *J. Biomed. Mater. Res.*, 38, 95, 104 (1997).
41. S. WAKITANI, T. GOTO, R. G. YOUNG, J. M. MANSOUR, V. M. GOLDBERG, A. I. CAPLAN, Repair of large full-thickness articular cartilage defects with allograft articular chondrocytes embedded in a collagen gel. *Tissue Eng.*, 4, 429, 444 (1998).
42. C. J. HUNTER, S. M. IMLER, P. MALAVIYA, R. M. NEREM, M. E. LEVENSTON, Mechanical compression alters gene expression and extracellular matrix synthesis by chondrocytes cultured in collagen I gels. *Biomaterials*, 23, 1249, 1259 (2002).
43. C. H. LEE, A. SINGLA, Y. LEE, Biomedical applications of collagen. *Int. J. Pharm.*, 221, 1–22, (2001).
44. L. MA, C. Y. GAO, Z. W. MAO, J. ZHOU, J. C. SHEN, X. Q. HU, C. M. HAN, Collagen/chitosan porous scaffolds with improved biostability for skin tissue engineering. *Biomaterials*, 24, 4833, 4841 (2003).
45. K. S. WEADOCK, E. J. MILLER, L. D. BELLINCAMPI, J. P. ZAWADSKY, M. G. DUNN, Physical crosslinking of collagen fibers: Comparison of ultraviolet irradiation and dehydrothermal treatment. *J. Biomed. Mater. Res.*, 29, 1373, 1379 (2004).
46. B. C. LIU, R. HARRELL, R. H. DAVIS, M. H. DRESDEN, M. SPIRA, The effect of gamma-irradiation on injectable human amnion collagen. *J. Biomed. Mater. Res.*, 23, 833, 844 (1989).
47. L. MA, C. Y. GAO, Z. W. MAO, J. C. SHEN, X. Q. HU, C. M. HAN, Thermal dehydration treatment and glutaraldehyde cross-linking to increase the biostability of collagen-chitosan porous scaffolds used as dermal equivalent. *J. Biomater. Sci. Polym. Ed.*, 14, 861, 874 (2003).
48. S. N. PARK, J. C. PARK, H. O. KIM, M. J. SONG, H. SUH, Characterization of porous collagen/hyaluronic acid scaffold modified by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide cross-linking. *Biomaterials*, 23, 1205, 1212 (2002).
49. B. HOYER, A. BERNHARDT, A. LODE, S. HEINEMANN, J. SEWING, M. KLINGER, H. NOTBOHM, M. GELINSKY, Jellyfish collagen scaffolds for cartilage tissue engineering. *Acta Biomaterialia*, 10, 883, 892 (2014).
50. F.L. MI, Y. C. TAN, H. F. LIANG, H. W. SUNG. In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant, *Biomaterials*, 23, 181, 191 (2002).
51. Y. YUAN, B. M. CHESNUTT, G. UTTURKAR, W. O. HAGGARD, Y. YANG, J. L. ONG, J. D. BUMGARDNER. The effect of cross-linking of chitosan microspheres with genipin on protein release. *Carbohydr. Polym.*, 68, 561, 567 (2007).
52. V. CHIONO, E. PULIERI, G. VOZZI, G. CIARDELLI, A. AHLUWALIA, P. GIUSTI, Genipin-crosslinked chitosan/gelatin blends for biomedical applications. *J. Mater. Sci. Mater. Med.*, 19, 889, 898 (2008).
53. L. P. YAN, Y. J. WANG, L. REN, G. WU, S. G. CARIDADE, J. B. FAN, L. Y. WANG, P. H. JI, J. M. OLIVEIRA, J. T. OLIVEIRA, J. F. MANO, R. L. REIS, Genipin-cross-linked collagen/chitosan biomimetic articular cartilage tissue engineering applications, folding. *J. Biomed. Mater. Res. Part. A*, 95, 465, 475, (2010).
54. L. BI, Z. CAO, Y. HU, Y. SONG, L. YU, B. YANG, J. MU, Z. HUANG, Y. HAN, Effects of different cross-linking conditions on the properties of genipin-cross-linked chitosan/collagen scaffolds for cartilage tissue engineering. *J. Mater. Sci.: Mater. Med.*, 22, 51, 62 (2011).
55. S. WAKITANI, T. KIMURA, A. HIROOKA, T. OCHI, M. YONEDA, N. YASUI, H. OWAKI, K. ONO, Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. *J. Bone Joint Surg.*, 71, 74, 80 (1989).
56. S. MIZUNO, F. ALLEMANN, J. GLOWACKI, Effects of medium perfusion on matrix production by bovine chondrocytes in three-dimensional collagen sponges. *J. Biomed. Mater. Res.*, 56, 368, 375 (2001).
57. M. OCHI, Y. UCHIO, K. KAWASAKI, S. WAKITANI, J. IWASA, Transplantation of cartilage-like tissue made by tissue engineering in treatment of cartilage defects of the knee. *J. Bone Joint Surg.*, 84, 571, 578 (2002).
58. C. R. LEE, A. J. GRODZINSKY, M. SPECTOR, Biosynthetic response of passaged chondrocytes in a type II collagen scaffold to mechanical compression. *J. Biomed. Mater. Res.*, 64, 560, 569 (2003).
59. P. CHERUBINO, F. A. GRASSI, P. BULGHERONI, M. RONGA, Autologous chondrocyte implantation using a bilayer collagen membrane. *J. Orthop. Surg. (Hong Kong)*, 11, 10, 15 (2003).
60. S. ANDEREYA, U. MAUS, K. GAVENIS, R. MULLER-RATH, O. MILTNER, T. MUMME T, U. SCHNEIDER, First clinical expression with a novel 3D-collagen gel (CaRes(R)) for the treatment of focal cartilage defects in the knee. *Z. Orthop. Ihre Grenzgeb.*, 144, 272, 280 (2006).

61. G. MAOR, K. VON DER MARK, H. REDDI, D. HEINEGARD, A. FRANZEN, M. SILBERMANN. Acceleration of cartilage and bone differentiation on collagenous substrata. *Collagen Rel. Res.*, 7, 351, 370 (1987).
62. A. BEN-YISHAY, D. A. GRANDE, D. MENCHE, M. PITMAN, Repair of articular cartilage defects using collagen-chondrocyte allografts. *Tissue Eng.* 1, 119, 133 (1992).
63. A. J. NIXON, A. E. SAMS, G. LUST, D. A. GRANDE, H. MOHAMMED, Temporal matrix synthesis and histologic features of a chondrocyte-laden porous collagen cartilage analogue. *Am. J. Vet. Res.*, 54, 349, 356 (1993).
64. A. E. SAMS, A. J. NIXON, Chondrocyte-laden collagen scaffolds for resurfacing extensive articular cartilage defects. *Osteoarthritis Cart.*, 3, 47, 59 (1995).
65. A. E. SAMS, R. R. MINOR, J. A. M. WOOTTON, H. MOHAMMED, A. J. NIXON, Local and remote matrix responses to chondrocyte-laden collagen scaffold implantation in extensive articular cartilage defects. *Osteoarthritis Cart.*, 3, 61, 70 (1995).
66. R. M. CAPITO, M. SPECTOR, Collagen scaffolds for nonviral IGF-1 gene delivery in articular cartilage tissue engineering. *Gene Therapy*, 14, 721, 732 (2007).
67. S. S. SILVA, A. MOTTA, M. T. RODRIGUES, A. F. M. PINHEIRO, M. E. GOMES, J. F. MANO, R. L. REIS, C. MIGLIARESI, Novel genipin-cross-linked chitosan/silk fibroin sponges for cartilage engineering strategies. *Biomacromolecules*, 9, 2764, 2774 (2008).
68. F. ALLEMANN, S. MIZUNO, K. EID, K.E. YATES, D. ZALESKE, J. GLOWACKI, Effects of hyaluronan on engineered articular cartilage extracellular matrix gene expression in 3-dimensional collagen scaffolds. *J. Biomed. Mater. Res.*, 55, 13, 19, (2001).
69. Q. ZHANG, H. LU, N. KAWAZOE, G. CHEN, Pore size effect of collagen scaffolds on cartilage regeneration. *Acta Biomaterialia*, 10(5), 2005, 2013 (2014)
70. U. SCHNEIDER, B.SCHMIDT-ROHLFING, K. GAVENIS, U. MAUS, R. MUELLER-RATH, S. ANDEREYA, A comparative study of 3 different cartilage repair techniques. *Knee Surg. Sports Traumatol. Arthrosc.*, 19(12), 2145, 2152 (2011).
71. L. DE GIROLAMO, G. BERTOLINI, M. CERVELLIN, G. SOZZI, P. VOLPI, Treatment of chondral defects of the knee with one step matrix-assisted technique enhanced by autologous concentrated bone marrow: in vitro characterisation of mesenchymal stem cells from iliac crest and subchondral bone. *Injury*, 41, 1172, 1177 (2010).
72. J. P. BENTHIEN, P. BEHRENS, Autologous matrix-induced chondrogenesis (AMIC). A one-step procedure for retropatellar articular resurfacing. *Acta Orthop Belg.*, 76, 260, 263 (2010).
73. J. P. BENTHIEN, P. BEHRENS. The treatment of chondral and osteochondral defects of the knee with autologous matrix-induced chondrogenesis (AMIC): method description and recent developments, *Knee Surg. Sports Traumatol. Arthrosc.*, 19, 1316, 1319 (2011).
74. J. GILLE, E. SCHUSEIL, J. WIMMER, J. GELLISSEN, A. P. SCHULZ, P. BEHRENS, Mid-term results of autologous matrix-induced chondrogenesis for treatment of focal cartilage defects in the knee. *Knee Surg. Sports Traumatol. Arthrosc.*, 18(11), 1456, 1464 (2010).
75. A. A. DHOLLANDER, F. DE NEVE, K. F. ALMQVIST, R. VERDONK, S. LAMBRECHT, D. ELEWAUT, G. VERBRUGGEN, P. C. VERDONK, Autologous matrix-induced chondrogenesis combined with platelet-rich plasma gel: technical description and a five pilot patients report. *Knee Surg. Sports Traumatol. Arthrosc.*, 19(4), 536, 542 (2011).
76. T. EFE, C. THEISEN, S. FUCHS-WINKELMANN, T. STEIN, A. GETGOOD, M. B. ROMINGER, J. R. J. PALETTA, M. D. SCHOFER, Cell-free collagen type I matrix for repair of cartilage defects-clinical and magnetic resonance imaging results. *Knee Surg. Sports Traumatol. Arthrosc.*, 20(10), 1915, 1922 (2012).
77. T. KUSANO, R. P. JAKOB, E. GAUTIER E, R. A. MAGNUSSEN, H. HOOGEWOUDE, M. JACOBI, Treatment of isolated chondral and osteochondral defects in the knee by autologous matrix-induced chondrogenesis (AMIC). *Knee Surg. Sports Traumatol. Arthrosc.*, 20(10), 2109, 2115 (2012).
78. A. A. SHETTY, S. J. KIM, P. BILAGI, D. STELZENEDER, Autologous Collagen-induced Chondrogenesis: Single-stage Arthroscopic Cartilage Repair Technique. *Orthopedics*, 36(5) 648, 652 (2013)
79. P. B. MALAFAYA, A. J. PEDRO, A. PETERBAUER, C. GABRIEL, H. REDL, R. L. REIS, Chitosan particles agglomerated scaffolds for cartilage and osteochondral tissue engineering approaches with adipose tissue derived stem cells. *J. Mater. Sci.: Mater. Med.*, 16, 1077, 1085 (2005).
80. N. IWASAKI, S. T. YAMANE, T. MAJIMA, Y. KASAHARA, A. MINAMI, K. HARADA, S. NONAKA, N. MAEKAWA, H. TAMURA, S. TOKURA, M. SHIONO, K. MONDE, S. I. NISHIMURA, Feasibility of polysaccharide hybrid materials for scaffolds in cartilage tissue engineering: Evaluation of chondrocyte adhesion to polyion complex fibers prepared from alginate and chitosan. *Biomacromolecules*, 5, 828, 833 (2004).

81. J. M. ZALESKAS, B. KINNER, T. M. FREYMAN, I. V. YANNAS, L. J. GIBSON, M. SPECTOR, Growth factor regulation of smooth muscle actin expression and contraction of human articular chondrocytes and meniscal cells in a collagen–GAG matrix. *Exp. Cell. Res.*, 270, 21, 31 (2001).
82. D. W. HUTMACHER, Scaffolds in tissue engineering bone and cartilage. *Biomaterials*, 21, 2529, 2543 (2000).
83. F. T. MOUTOS, L. E. FREED, F. GUILAK, A biomimetic three-dimensional woven composite scaffold for functional tissue engineering of cartilage. *Nat. Mater.*, 6, 162, 167 (2007).
84. Z. LI, S.-J. YAO, M. ALINI, M. J. STODDART, Chondrogenesis of human bone marrow mesenchymal stem cells in fibrin-polyurethane composites is modulated by frequency and amplitude of dynamic compression and shear stress. *Tissue Eng. Part. A*, 16, 575, 584 (2010).
85. J. T. OLIVEIRA, A. CRAWFORD, J. M. MUNDY, A. R. MOREIRA, M. E. GOMES, P. V. HATTON, R. L. REIS, A cartilage tissue engineering approach combining starch-polycaprolactone fibre mesh scaffolds with bovine articular chondrocytes. *J. Mater. Sci. Mater. Med.*, 18, 295, 302 (2007).
86. P. PRABU, N. DHARMARAJ, A. SANTOSH, B. M. LEE, R. VIJAYA, H. Y. KIM, Preparation and drug release activity of scaffolds containing collagen and poly (caprolactone). *J. Biomed. Mater. Res.*, 79, 153, 158 (2006).
87. W. DAI, N. KAWAZOE, X. LIN, J. DONG, G. CHEN, The influence of structural design of PLGA/collagen hybrid scaffolds in cartilage tissue engineering. *Biomaterials*, 31, 2141, 2152 (2010).
88. T. SATO, G. CHEN, T. USHIDA, T. ISHII, N. OCHIAI, T. TATEISHI, Tissue-engineered cartilage by in vivo culturing of chondrocytes in PLGA–collagen hybrid sponge. *Mater. Sci. Eng. C.*, 17, 83–89 (2001).
89. G. CHEN, T. SATO, T. USHIDA, N. OCHIAI, T. TATEISHI, Tissue engineering of cartilage using a hybrid scaffold of synthetic polymer and collagen. *Tissue Eng.*, 10, 323, 330 (2004).
90. G. CHEN, T. USHIDA, T. TATEISHI, A biodegradable hybrid sponge nested with collagen microsponges. *J. Biomed. Mater. Res.*, 51, 273, 279 (2000).
91. C. T. LEE, C. P. HUANG, Y. D. LEE, Biomimetic porous scaffolds made from poly(L-lactide)-g-chondroitin sulfate blend with poly(L-lactide) for cartilage tissue engineering. *Biomacromolecules*, 7, 2200, 2209 (2006).
92. K.Y. CHANG, L.H. HUNG, I.M. CHU, C.S. KO, Y.D. LEE, The application of type II collagen and chondroitin sulfate grafted PCL porous scaffold in cartilage tissue engineering. *J. Biomed. Mater. Res. Part. A*, 92, 712, 723 (2010).
93. A. M. HAAPARANTA, E. JÄRVINEN, I. F. CENGİZ, V. ELLÄ, H. T. KOKKONEN, I. KIVIRANTA, M. KELLOMÄKI, Preparation and characterization of collagen/PLA, chitosan/PLA, and collagen/chitosan/PLA hybrid scaffolds for cartilage tissue engineering. *J. Mater. Sci.: Mater. Med.*, 25, 1129, 1136 (2014).
94. M. KEENEY, J. H. LAI, F. YANG, Recent progress in cartilage tissue engineering. *Curr. Opin. Biotechnol.*, 22(5), 734, 740 (2011).
95. T. MIMURA, S. IMAI, M. KUBO, E. ISOYA, K. ANDO, N. OKUMURA, Y. MATSUSUE, A novel exogenous concentration-gradient collagen scaffold augments full-thickness articular cartilage repair. *Osteoarthritis Cart.*, 16, 1083, 1091 (2008).
96. R. E. SAMUEL, C. R. LEE, S. GHIVIZZANI, C. H. EVANS, I. V. YANNAS, B. R. OLSEN, M. SPECTOR, Delivery of plasmid DNA to articular chondrocytes via novel collagen-glycosaminoglycan matrices. *Hum Gene Ther* 13, 791, 802 (2002).
97. L. D. SHEA, E. SMILEY, J. BONADIO, D. J. MOONEY, DNA delivery from polymer matrices for tissue engineering. *Nat. Biotech.*, 17, 551, 554 (1999).
98. J. H. JANG, L. D. SHEA, Controllable delivery of non-viral DNA from porous scaffolds. *J Control Release*, 86, 157, 168 (2003).
99. Y. K. LUU, K. KIM, B. S. HSIAO, B. CHU, M. HADJIARGYROU, Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. *J. Control Release*, 89, 341, 353 (2003).
100. H. S. NANDA, S. CHEN, Q. ZHANG, N. KAWAZOE, G. CHEN, Collagen Scaffolds with Controlled Insulin Release and Controlled Pore Structure for Cartilage Tissue Engineering. *BioMed Research International*, Article ID 623805 (2014).